Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/52453
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Connolly E. | - |
dc.contributor.author | White M. | - |
dc.contributor.author | Siva S. | - |
dc.contributor.author | Bressel M. | - |
dc.contributor.author | Tan J. | - |
dc.contributor.author | Byrne K. | - |
dc.contributor.author | Day D. | - |
dc.contributor.author | McCartney A. | - |
dc.contributor.author | Webber K. | - |
dc.contributor.author | David S.P. | - |
dc.date.accessioned | 2024-09-16T05:41:57Z | - |
dc.date.available | 2024-09-16T05:41:57Z | - |
dc.date.copyright | 2024 | - |
dc.date.issued | 2024-09-02 | en |
dc.identifier.citation | International Journal of Radiation Oncology Biology Physics. Conference: 2024 ASTRO Annual Meeting. Walter E. Washington Convention Center, Washington United States. 120(2 Supplement) (pp e304), 2024. Date of Publication: 01 Oct 2024. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/52453 | - |
dc.description.abstract | Purpose/Objective(s): The AVATAR I Trial demonstrated that oligoprogressive luminal (ER positive, HER2 negative) advanced breast cancer patients undergoing established first-line systemic therapy for metastatic disease benefited from SRT as second-line therapy along with their original systemic treatment. A modified PFS, defined as a disease progression not amenable to SRT treatment, was reported as 10.4 months. Given this result, this trial in progress seeks to assess if SRT combined with systemic therapy CDK4/6 inhibitor and Aromatase Inhibitor (CDK4/6+AI) can improve the Quality of Life (QoL) for this cohort of patients. Materials/Methods: AVATAR II is a Phase 2 randomized control trial that enrolls patients with advanced luminal breast cancer who have received first-line systemic treatment in the metastatic setting with a CDK4/6+AI. Patients require at least 1 extracranial oligoprogressing lesion amenable to SRT. Patients who had chemotherapy for metastatic disease, leptomeningeal disease, or prior radiotherapy to an oligoprogressing lesion were excluded. Patients were randomized to Arm A; SRT to all oligoprogressing lesions and continue CDK4/6+AI systemic therapy or Arm B; no SRT and review to assess if a change in systemic therapy is required. If a patient subsequently progresses, further SRT was permitted to delay a change in systemic therapy in patients who had received SRT as part of the trial. At 3-monthly reviews, patient reported outcomes are measured using the EORTC QLQ C30 and FACT-B forms. The trial is expected to recruit 74 patients. The primary endpoint is the area under the curve (AUC) of the Quality of Life/Global Health Status score from the EORTC QLQ-C30 from baseline to the 12-month follow-up visit. The secondary endpoints are to determine Progression-free Survival (PFS) and PFS 2, defined as the time from randomization to the date of first and second evidence of progression, respectively. Other secondary endpoints include ST-PFS, defined as randomization to the first evidence of progression requiring change in systemic therapy, Overall Survival, treatment-related toxicity and further QoL assessment using AUC of the FACT-B Total score from baseline to 12 months. Result(s): TBD. Conclusion(s): Assessing quality of life (QoL) is integral to evaluating the overall impact of cancer treatment. AVATAR II aims to demonstrate that by delaying a change in systemic therapy and potentially more potent side effects, receiving SRT at this stage in a patient's treatment paradigm will have a more positive impact on patients' QoL.Copyright © 2024 | - |
dc.publisher | Elsevier Inc. | - |
dc.relation.ispartof | International Journal of Radiation Oncology Biology Physics | - |
dc.subject.mesh | breast cancer | - |
dc.subject.mesh | radiotherapy | - |
dc.title | Stereotactic radiotherapy (SRT) with maintenance systemic therapy vs. standard-of-care (SOC) systemic therapy for oligoprogressive ER-positive, HER2-negative breast cancer (AVATAR-II). | - |
dc.type | Conference Abstract | - |
dc.identifier.affiliation | Oncology | - |
dc.description.conferencename | 2024 ASTRO Annual Meeting | - |
dc.description.conferencelocation | Walter E. Washington Convention Center, Washington, United States | - |
dc.type.studyortrial | Observational study (cohort, case-control, cross sectional, or survey) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.ijrobp.2024.07.674 | - |
local.date.conferencestart | 2024-09-29 | - |
dc.identifier.institution | (Connolly, Siva, Tan, Byrne, David) Peter MacCallum Cancer Centre, Melbourne, VIC, Australia | - |
dc.identifier.institution | (White, Day, McCartney, Webber) Department of Oncology, Monash Health, Melbourne, VIC, Australia | - |
dc.identifier.institution | (Bressel) Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia | - |
local.date.conferenceend | 2024-10-02 | - |
dc.identifier.affiliationmh | (White, Day, McCartney, Webber) Department of Oncology, Monash Health, Melbourne, VIC, Australia | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Conference Abstract | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology | - |
Appears in Collections: | Conferences |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.